Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug;109(5):534-9.
doi: 10.1590/0074-0276130579.

Emerging Plasmodium vivax resistance to chloroquine in South America: an overview

Affiliations
Review

Emerging Plasmodium vivax resistance to chloroquine in South America: an overview

Lígia Antunes Gonçalves et al. Mem Inst Oswaldo Cruz. 2014 Aug.

Abstract

The global emergence of Plasmodium vivax strains resistant to chloroquine (CQ) since the late 1980s is complicating the current international efforts for malaria control and elimination. Furthermore, CQ-resistant vivax malaria has already reached an alarming prevalence in Indonesia, East Timor and Papua New Guinea. More recently, in vivo studies have documented CQ-resistant P. vivax infections in Guyana, Peru and Brazil. Here, we summarise the available data on CQ resistance across P. vivax-endemic areas of Latin America by combining published in vivo and in vitro studies. We also review the current knowledge regarding the molecular mechanisms of CQ resistance in P. vivax and the prospects for developing and standardising reliable molecular markers of drug resistance. Finally, we discuss how the Worldwide Antimalarial Resistance Network, an international collaborative effort involving malaria experts from all continents, might contribute to the current regional efforts to map CQ-resistant vivax malaria in South America.

PubMed Disclaimer

Figures

None
Map showing sites of recent in vivo studies of chloroquine treatment for Plasmodium vivax infections in South America (published between 2000-2013). Triangles indicate study sites where treatment failures have been reported, while squares indicate sites with no treatment failures observed over 28 days of follow-up. Note the close proximity between two sites in Colombia (Uraba and Turbo) and two sites in Bolivia (Riberalta and Guayaramerín). Clinical data are from Villalobos-Salcedo et al. (2000) (Porto Velho, Brazil), Soto et al. (2001) (Uraba and Llanos Orientales, Colombia), Baird et al. (2002) (Georgetown, Guyana), Ruebush et al. (2003) (Iquitos, Caballococha and Sullana, Peru), Alvarez et al. (2006) (Turbo and El Bagre, Colombia), de Santana Filho et el. (2007) (Manaus, Brazil), Osorio et al. (2007) (Tarapacá, Colombia), Carmona-Fonseca and Maestre (2009) (Turbo and El Bagre, Colombia), Añez et al. (2012) (Riberalta, Guayaramerín and Yacuiba, Bolivia) and Marques et al. (2013) (Manaus, Brazil). Shading patterns vary according to P. vivax malaria prevalence (PvPR) data estimated by Gething et al. (2012).

References

    1. Alvarez G, Piñeros JG, Tobón A, Ríos A, Maestre A, Blair S, Carmona-Fonseca J. Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. Am J Trop Med Hyg. 2006;75:605–609. - PubMed
    1. Añez A, Navarro-Costa D, Yucra O, Garnica C, Melgar V, Moscoso M, Arteaga R, Nakao G. Therapeutic response of Plasmodium vivax to chloroquine in Bolivia. Biomedica. 2012;32:527–535. - PubMed
    1. Arevalo-Herrera M, Quiñones ML, Guerra C, Céspedes N, Giron S, Ahumada M, Piñeros JG, Padilla N, Terrientes Z, Rosas A, Padilla JC, Escalante AA, Beier JC, Herrera S. Malaria in selected non-Amazonian countries of Latin America. Acta Trop. 2012;121:303–314. - PMC - PubMed
    1. Arias AE, Corredor A. Low response of Colombian strains of Plasmodium vivax to classical antimalarial therapy. Trop Med Parasitol. 1989;40:21–23. - PubMed
    1. Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev. 2009;22:508–534. - PMC - PubMed

Publication types

MeSH terms